Clinical Research

Overview

Clinical research institutions, universities and academic medical centers, pharmaceutical companies, medical device manufacturers, and other health and life sciences industry organizations are focused on protecting and leveraging their investments in research, development, and innovation. We provide critical counseling to help preserve your assets, mitigate regulatory risk, and get your products to market as expediently as possible. From clinical trials and product design to premarket approval and product launch, our team of attorneys and other professionals guides you in carefully crafting clinical trial, licensing, research and development, and other agreements; obtaining appropriate patents or other intellectual property protection; obtaining FDA and other regulatory approvals; addressing reimbursement strategies; and preparing for product liability defenses. We help you take advantage of federal tax exemptions, strategically change clinical trial processes or product designs, and conduct evidence-based advocacy to enhance federal support for areas of distinction. We are recognized for our work with clients in the areas of orphan drugs, patient-focused drug development, pediatrics, and Alzheimer’s disease, among many others, and work with you to develop and win approval of treatments and medications that address some of today’s most pressing, unmet needs. We have the experience to help bring innovation to the industry and, most importantly, to patients.

Insights & Events

Latest

最新 April 2026

FDA-Related Legislative and Regulatory Proposals and Funding Change the President's FY27 Budget

Between a Doorstop and a Starting Gun
121 min read
News April 2026

Jennifer Breuer Named a 2026 ‘Notable Leaders in Health Care’ Honoree by Crain’s Chicago Business

1 min read
最新 April 2026

The Intel Report: Quarterly National Security Briefing

Key Regulatory Developments and Enforcement Actions Affect National Security Priorities, Risks, and Opportunities across Sectors
14 min read
最新 February 2026

UK Data (Use and Access) Act 2025: Update and New Compliance Challenges

“Right to Complain” will come into force 19 June 2026
6 min read
最新 February 2026

FDA Publishes Long-Awaited Draft Guidance on “Plausible Mechanism Framework” to Spur the Development of New Individualized Medicines

Anticipated Deadline for Comments Is April 27, 2026
7 min read
媒体报道 January 2026

Nick Manetto Discusses Future of Federal PBM Spread Pricing Bill With Inside Health Policy

1 min read
最新 December 2025

European Union’s Digital Omnibus Package, Part II — Changes to the GDPR and the Data Act

Key Changes Relevant to U.S. Businesses
9 min read
Speaking Engagement Recap November 07, 2025

Data, Dangers, & Developments in Drug Supply Chain Security & Safety

American Society for Pharmacy Law: 2025 Developments in Pharmacy Law
1 min read
Speaking Engagement Recap October 17, 2025

Privacy and Genetic Data

European Health Data Protection Congress
1 min read
Press Release May 2025

Faegre Drinker Welcomes Former Senate HELP Committee General Counsel Barrett Tenbarge to Government and Regulatory Group

3 min read
Insights
最新 April 2026

FDA-Related Legislative and Regulatory Proposals and Funding Change the President's FY27 Budget

Between a Doorstop and a Starting Gun
121 min read
最新 April 2026

The Intel Report: Quarterly National Security Briefing

Key Regulatory Developments and Enforcement Actions Affect National Security Priorities, Risks, and Opportunities across Sectors
14 min read
最新 February 2026

UK Data (Use and Access) Act 2025: Update and New Compliance Challenges

“Right to Complain” will come into force 19 June 2026
6 min read
最新 February 2026

FDA Publishes Long-Awaited Draft Guidance on “Plausible Mechanism Framework” to Spur the Development of New Individualized Medicines

Anticipated Deadline for Comments Is April 27, 2026
7 min read
媒体报道 January 2026

Nick Manetto Discusses Future of Federal PBM Spread Pricing Bill With Inside Health Policy

1 min read
最新 December 2025

European Union’s Digital Omnibus Package, Part II — Changes to the GDPR and the Data Act

Key Changes Relevant to U.S. Businesses
9 min read
最新 November 2025

Potential Challenges to State AI Laws; Senate Hearing on AI; and More Developments

Artificial Intelligence Briefing
6 min read
最新 November 2025

SCOTUS Weighs Trump Administration’s Tariff Authority Under IEEPA; Pharma and Device AI; and More

Biopharma & Medical Devices Briefing
7 min read
发表文章 October 2025

Defining Child Health Research to Guide Equitable Federal Appropriations

Journal of Pediatrics
1 min read
最新 August 2025

‘America’s AI Action Plan’ and More Developments for the Tech, Financial Services, Insurance and Health Care Sectors

Artificial Intelligence Briefing
8 min read

Meet The Team

Meet The Team